Kurma Partners and Angelini Ventures led a $45m Series B round in Nuevocor.

Kurma Partners and Angelini Ventures led a $45m Series B round in Nuevocor, a Singapore-headquartered IND-stage biotechnology company, with participation from EDBI, ClavystBio and Boehringer Ingelheim Venture Fund, alongside Highlight Capital and SEEDS Capital. "We are delighted to secure this significant financing milestone to build a global company with such an experienced syndicate of international life science investors.The continued strong support from insiders and the addition of new investors will enable Nuevocor to continue its strong momentum and advance NVC-001 into the clinic. This is an example of how Singapore is bringing transformative innovation to the rest of the world," Yann Chong Tan, Nuevocor CEO and Co-Founder.